Search results for "VIRUS-INFECTION"

showing 10 items of 13 documents

Cognate HLA absence in trans diminishes human NK cell education

2016

NK cells are innate lymphocytes with protective functions against viral infections and tumor formation. Human NK cells carry inhibitory killer cell Ig-like receptors (KIRs), which recognize distinct HLAs. NK cells with KIRs for self-HLA molecules acquire superior cytotoxicity against HLA– tumor cells during education for improved missing-self recognition. Here, we reconstituted mice with human hematopoietic cells from donors with homozygous KIR ligands or with a mix of hematopoietic cells from these homozygous donors, allowing assessment of the resulting KIR repertoire and NK cell education. We found that co-reconstitution with 2 KIR ligand–mismatched compartments did not alter the frequenc…

0301 basic medicine10028 Institute of Medical VirologyEpstein-Barr Virus InfectionsHerpesvirus 4 HumanCellchemical and pharmacologic phenomena610 Medicine & healthMice SCIDHuman leukocyte antigen2700 General MedicineAdaptive ImmunityBiology10263 Institute of Experimental Immunology03 medical and health sciencesMice Inbred NOD10049 Institute of Pathology and Molecular PathologymedicineAnimalsHumansCytotoxicityReceptorHistocompatibility Antigens Class IHEK 293 cellsGeneral MedicineAcquired immune systemKiller Cells NaturalHaematopoiesisHEK293 Cells030104 developmental biologymedicine.anatomical_structureNatural-Killer-Cells Cord Blood Transplantation Cytomegalovirus-Infection Class-I Inhibitory receptors Pediatric Patients TumorsImmunologyK562 CellsResearch ArticleK562 cells
researchProduct

Novel activities of safe-in-human broad-spectrum antiviral agents

2018

According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley feve…

0301 basic medicineviruksetviruses030106 microbiologyAPPROVED DRUGSHEPATITIS-C VIRUSINFLUENZA-A VIRUSBioinformaticsAntiviral AgentsArticle03 medical and health sciencesBroad spectrumVirologyHumansRNA VirusesvirusesCELL-CULTUREPharmacologyZIKA VIRUS-INFECTIONviral diseasesECHOVIRUS 1ta1183DNA VirusesDrug Repositioningta1182MOUSE MODELLIVER-TRANSPLANTATION3. Good healthDrug repositioning030104 developmental biology317 PharmacyVirus DiseasesvirustauditENTRY3111 BiomedicineViral diseaseINHIBITORSAntiviral Research
researchProduct

Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins

2017

Viral diseases remain serious threats to public health because of the shortage of effective means of control. To combat the surge of viral diseases, new treatments are urgently needed. Here we show that small-molecules, which inhibit cellular anti-apoptotic Bcl-2 proteins (Bcl-2i), induced the premature death of cells infected with different RNA or DNA viruses, whereas, at the same concentrations, no toxicity was observed in mock-infected cells. Moreover, these compounds limited viral replication and spread. Surprisingly, Bcl-2i also induced the premature apoptosis of cells transfected with viral RNA or plasmid DNA but not of mock-transfected cells. These results suggest that Bcl-2i sensiti…

0301 basic medicinevirusesFAMILY INHIBITORSlcsh:QR1-502Virus Replicationlcsh:Microbiologychemistry.chemical_compoundTranscription (biology)SALIPHENYLHALAMIDEhost responseTRANSCRIPTIONprogrammed cell deathinnate immunity1183 Plant biology microbiology virologySulfonamidesAniline CompoundsapoptosisTransfection3. Good healthInfectious DiseasesProto-Oncogene Proteins c-bcl-2X-L INHIBITORVirus DiseasesvirustauditVirusesRNA ViralBiologyTransfectionta3111Antiviral AgentsArticleCell LineMicrobiology in the medical areaantiviral agent03 medical and health sciencesohjelmoitunut solukuolemaVirologyMikrobiologi inom det medicinska områdetHumansMetabolomicsBenzothiazolesInnate immune systemapoptosis; antiviral agent; innate immunity; host responseZIKA VIRUS-INFECTIONCHRONIC LYMPHOCYTIC-LEUKEMIAPOTENTta1183INFLUENZA-Ata1182RNAIsoquinolinesVirology030104 developmental biologyViral replicationchemistryCell cultureApoptosisCELLSREPLICATIONDNA Viral3111 BiomedicineDNA
researchProduct

Usefulness of routine hepatitis C and hepatitis B serology in the diagnosis of recent-onset arthritis. Systematic prospective screening in all patien…

2012

Ansemant, Thiphaine | Ornetti, Paul | Garrot, Jean-Francois | Pascaud, Francoise | Tavernier, Christian | Maillefert, Jean-Francis; International audience; ''Objective: Previous studies evaluating the usefulness of systematic screening for hepatitis B and C in patients with recent-onset arthritis suffered from a major bias since they were conducted in hospitals. The objective of the present study was to evaluate the relevance of such screening, performed by hospital and office-based rheumatologists of a defined area, in the diagnosis of arthritis or inflammatory polyarthralgia of less than 1 year duration. Methods: The CRRRI is a network which includes most hospital and office-based rheumat…

AdultMalemedicine.medical_specialtyPOLYARTHRITIS''PopulationVIRUS-INFECTIONUnnecessary Proceduresmedicine.disease_cause03 medical and health sciences0302 clinical medicineHepatitis B ChronicPOLYARTHRITISRheumatologySeroepidemiologic StudiesInternal medicineRheumatic DiseasesmedicineHumansMass ScreeningSerologic Tests030212 general & internal medicineProspective StudiesHepatitis B AntibodieseducationMass screeningAged030203 arthritis & rheumatologyHepatitis B viruseducation.field_of_studyOligoarthritisbusiness.industry[SCCO.NEUR]Cognitive science/Neuroscience''RHEUMATOID-ARTHRITISHepatitis CHepatitis BHepatitis C AntibodiesHepatitis C ChronicMiddle Agedmedicine.diseaseRheumatology3. Good healthRHEUMATOID-ARTHRITISMANIFESTATIONS[ SCCO.NEUR ] Cognitive science/NeuroscienceImmunologyPolyarthritisFemalebusinessBiomarkersJoint bone spine
researchProduct

Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplan…

2004

International audience; Background. Isolated case reports have shown that recipients of allogeneic hematopoietic stem cell transplants ( HSCTs) who develop toxoplasmosis may have circulating Toxoplasma gondii DNA in peripheral blood before the onset of clinical symptoms. Methods. We prospectively studied 106 T. gondii - seropositive adult recipients of HSCTs for the incidence of reactivation of toxoplasmosis in the first 6 months after transplantation. Toxoplasmosis infection ( TI) was defined by a positive result of polymerase chain reaction ( PCR) of peripheral blood specimens, whereas toxoplasmosis disease ( TD) was defined as an invasive infection. Results. The incidence of TI was 16% (…

AdultMicrobiology (medical)POLYMERASE-CHAIN-REACTIONmedicine.medical_treatment[SDV]Life Sciences [q-bio]Hematopoietic stem cell transplantationPolymerase Chain ReactionParasite loadCYTOMEGALOVIRUS-INFECTIONBlood cell03 medical and health sciencesIMMUNE RECONSTITUTION0302 clinical medicinemedicineAnimalsHumansTransplantation Homologous030212 general & internal medicineREAL-TIME PCR0303 health sciencesHematologic Testsbiology030306 microbiologybusiness.industryIncidence (epidemiology)Toxoplasma gondiiDNA Protozoanbiology.organism_classificationmedicine.diseaseBONE-MARROW-TRANSPLANTATIONPREEMPTIVE THERAPYToxoplasmosis3. Good healthTransplantationRECIPIENTSInfectious DiseasesReal-time polymerase chain reactionmedicine.anatomical_structureImmunologySTATISTICAL-METHODSTRANSFER HYBRIDIZATION PROBESbusinessToxoplasmaToxoplasmosisStem Cell Transplantation
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel.

2010

AbstractChelation therapy with new drugs prevents cardiac damage and improves the survival of thalassemia patients. Liver diseases have emerged as a critical clinical issue. Chronic liver diseases play an important role in the prognosis of thalassemia patients because of the high frequency of viral infections and important role of the liver in regulating iron metabolism. Accurate assessment of liver iron overload is required to tailor iron chelation therapy. The diagnosis of hepatitis B virus– or hepatitis C virus–related chronic hepatitis is required to detect patients who have a high risk of developing liver complications and who may benefit by antiviral therapy. Moreover, clinical manage…

Liver Cirrhosisthalassemiamedicine.medical_specialtyCirrhosisC VIRUS-INFECTION; HOMOZYGOUS BETA-THALASSEMIA; TRANSFUSION-DEPENDENT THALASSEMIA; TERM-FOLLOW-UP; IRON OVERLOAD; LIVER-DISEASE; INTERFERON-ALPHA; RISK-FACTORS; INTRAFAMILIAL TRANSMISSION; HEPATOCELLULAR-CARCINOMAHepatitis C virusThalassemiaImmunologymedicine.disease_causeChronic liver diseaseAntiviral AgentsBiochemistryHOMOZYGOUS BETA-THALASSEMIALiver diseaseHepatitis B ChronicLIVER-DISEASEHEPATOCELLULAR-CARCINOMAmedicineTRANSFUSION-DEPENDENT THALASSEMIAIRON OVERLOADHumansIntensive care medicineTERM-FOLLOW-UPchronic viral hepatitis; thalassemia; managementbusiness.industryCell BiologyHematologyHepatitis CHepatitis C ChronicHepatitis Bmedicine.diseaseINTRAFAMILIAL TRANSMISSIONchronic viral hepatitisImmunologyRISK-FACTORSINTERFERON-ALPHAViral hepatitisbusinessC VIRUS-INFECTIONmanagement
researchProduct

Unexplained chronic liver disease in Ethiopia: a cross-sectional study

2018

Background Hepatitis B virus (HBV) infection is assumed to be the major cause of chronic liver disease (CLD) in sub-Saharan Africa. The contribution of other aetiological causes of CLD is less well documented and hence opportunities to modulate other potential risk factors are being lost. The aims of this study were to explore the aetiological spectrum of CLD in eastern Ethiopia and to identify plausible underlying risk factors for its development. Methods A cross-sectional study was undertaken between April 2015 and April 2016 in two public hospitals in Harar, eastern Ethiopia. The study population comprised of consenting adults with clinical and radiological evidence of chronic liver dise…

MaleCross-sectional studyEpidemiologyBiopsyChronic liver disease0302 clinical medicineRisk FactorsKhatEpidemiologyPrevalenceSIMPLE NONINVASIVE INDEX030212 general & internal medicineViral hepatitisPOPULATIONbiologymedicine.diagnostic_testSub-Saharan AfricaLiver DiseasesGastroenterologyCHRONIC HEPATITISGeneral MedicineAlcoholismLiverLiver biopsyPopulation studyFemale030211 gastroenterology & hepatologyC HEPATITISViral hepatitisLife Sciences & BiomedicineResearch ArticleAdultmedicine.medical_specialtySubstance-Related DisordersAcute Lung InjuryKHAT LEAVESAUTOIMMUNEVERBAL AUTOPSY METHODCathaVIRUS-INFECTIONCatha edulis03 medical and health sciencesInternal medicinemedicineHumanslcsh:RC799-869Science & TechnologyGastroenterology & HepatologySIGNIFICANT FIBROSISbusiness.industryHepatotoxicity1103 Clinical SciencesHepatologybiology.organism_classificationmedicine.diseaseCross-Sectional StudiesChronic Diseaselcsh:Diseases of the digestive system. GastroenterologyEthiopiabusiness
researchProduct

Trends in congenital anomalies in Europe from 1980 to 2012

2018

Background Surveillance of congenital anomalies is important to identify potential teratogens. Methods This study analysed the prevalence of 61 congenital anomaly subgroups (excluding chromosomal) in 25 population-based EUROCAT registries (1980–2012). Live births, fetal deaths and terminations of pregnancy for fetal anomaly were analysed with multilevel random-effects Poisson regression models. Results Seventeen anomaly subgroups had statistically significant trends from 2003±2012; 12 increasing and 5 decreasing. Conclusions The annual increasing prevalence of severe congenital heart defects, single ventricle, atrioventricular septal defects and tetralogy of Fallot of 1.4% (95% CI: 0.7% to …

MaleMaternal HealthLimb Reduction Defectslcsh:MedicineHEART-DEFECTS030204 cardiovascular system & hematologyFOLIC-ACID FORTIFICATIONPathology and Laboratory MedicineGeographical Locations0302 clinical medicineEUROCATPregnancyDuctus arteriosusPrevalenceMedicine and Health SciencesMorphogenesis030212 general & internal medicineRegistrieslcsh:ScienceTetralogy of FallotRISKStenosiseducation.field_of_studyMultidisciplinaryObstetricsIncidence (epidemiology)Obstetrics and GynecologyHeartASSOCIATIONCongenital Heart DefectsCongenital AnomaliesEuropePOPULATION-BASED EVALUATIONmedicine.anatomical_structurecongenital anomalies ; surveillance epidemiologyPopulation SurveillanceMicrocephalyNEURAL-TUBE DEFECTSFemaleAnatomyResearch Articlemedicine.medical_specialtyCardiac VentriclesPopulationCardiologyHistory 21st CenturyDuodenal atresiaEurope/epidemiologyCongenital Abnormalities03 medical and health sciencesSigns and SymptomsDiagnostic MedicinemedicineCongenital DisordersHumansBirth DefectseducationPregnancyZIKA VIRUS-INFECTIONbusiness.industrylcsh:RBiology and Life SciencesHistory 20th Centurymedicine.diseaseCongenital Abnormalities/diagnosisCongenital Abnormalities/diagnosis; Congenital Abnormalities/epidemiology; Congenital Abnormalities/etiology; Congenital Abnormalities/history; Europe/epidemiology; Female; History 20th Century; History 21st Century; Humans; Male; Population Surveillance; Pregnancy; Prevalence; RegistriesTeratologyREDUCTIONAtresiaPeople and PlacesBirthCardiovascular AnatomyVentricular Septal DefectsWomen's Healthlcsh:QbusinessDevelopmental BiologyPLoS One
researchProduct

Prevalence of microcephaly in Europe: population based study.

2016

Objectives: Microcephaly is a congenital anomaly where the baby’s head is smaller than expected when compared with babies of the same sex, age and ethnicity. Many of these babies will have underdeveloped brains. This study aimed to provide contemporary estimates of the prevalence of microcephaly in Europe, determine if the diagnosis of microcephaly is consistent across Europe and to evaluate whether changes in prevalence would be detected using the current European surveillance performed by EUROCAT (the European Surveillance of Congenital Anomalies). Design: A questionnaire and a population-based, observational study Setting: 24 EUROCAT registries covering 570,000 births annually in 15 coun…

MalePediatricsmedicine.medical_specialtyMicrocephalyPrenatal diagnosisEthnic originmicrocephaly ; prevalence surveillance03 medical and health sciencessymbols.namesakeEuropean Surveillance of Congenital Anomalies0302 clinical medicineMicrocefaliaEuropean SurveillancePregnancyEUROCAT030225 pediatricsStatistical significancePrenatal DiagnosisSurveys and QuestionnairesmedicinePrevalenceJournal ArticleHumans030212 general & internal medicinePoisson regressionRegistriesEurope/epidemiology; Female; Fetal Death; Humans; Male; Microcephaly/diagnosis; Microcephaly/epidemiology; Population Surveillance; Pregnancy; Prenatal Diagnosis; Prevalence; Registries; Retrospective Studies; Surveys and QuestionnairesFetal DeathRetrospective StudiesPregnancyZIKA VIRUS-INFECTIONbusiness.industryResearchRENACRetrospective cohort studyGeneral Medicinemedicine.diseaseEstados de Saúde e de DoençaObservação em Saúde e VigilânciaCongenital AnomaliesConfidence intervalEuropeCONGENITAL-ANOMALIESPopulation SurveillancesymbolsMicrocephalyFemalebusiness
researchProduct